Business
Quest PharmaTech to Market and Distribute Premium Anti-Wrinkle Skin Care Product, Bellus Skin(TM); Dr. Jacqueline Shan, Creator of COLD FX®, to Assist
TSX Venture: QPT EDMONTON , Oct. 22, 2014 /CNW/ - Quest PharmaTech Inc. (TSX-V: QP...
About this update from Quest Pharmatech Inc.
[{"type":"text","content":"\n\n\n\n\nTSX Venture: QPT\n\n\n\nEDMONTON, Oct. 22, 2014 /CNW/ - Quest PharmaTech Inc. (TSX-V: QPT) (\"Quest\" or the \"Company\"), a pharmaceutical company developing and commercializing products for the treatment of cancer, reports today that it has signed an exclusive supply and distribution agreement with Smart Cell Tec for the world-wide marketing and distribution rights, excluding South Korea, for the science based, premium anti-wrinkle skin care product, Bellus Skin™.\n\nBellus Skin™ has several unique qualities that make it an effective high end anti-wrinkle serum.  The patented SP Technology in Bellus Skin™ enables superior penetration of the key ingredients to the lower layers of the skin surface where the effect is profound and long lasting. The SP Technology platform, developed by the Korean company, Bioceltran Co., Ltd., also has applications for other cosmetic and pharmaceutical products under development. Quest has exclusive rights to SP Technology based products. In addition, Quest recently acquired equity in Bioceltran, thereby enabling plans to create a revenue stream for Quest in the near term. \n\n\"I am pleased that we are able to add this high quality product to our existing technologies and help build shareholder value through sales by Quest under this marketing and distribution agreement\" said Dr. Madi Madiyalakan, CEO of Quest.  \"Bellus Skin™ is a science based premium anti-wrinkle skin care product already being sold in Korea.  Pre-market testing feedback for the product has been highly favorable. In addition, SP Technology when used in combination with Quest's SonoLight technology has some unique advantages both for dermatology and oncology applications.\"\n\nTo assist Quest with the Canadian and U.S. marketing strategy for Bellus Skin™, Quest has entered into a marketing and distribution relationship with Afinity Life Sciences Inc., headed by Dr. Jacqueline Shan, founder and former CEO and Chief Science Officer of Afexa Life Sciences Inc. who successfully developed and commercialized the #1 selling product COLDFX ®.  \n\nQuest has also recently signed an exclusive distribution agreement with Global Persada International, a Singapore based company managed by Dr. Rikrik Ilya, CEO of Innokeys Pte Ltd., for marketing of Bellus Skin in ASEAN co...